Minireview: Potassium channels and aldosterone dysregulation: Is primary aldosteronism a potassium channelopathy?

Endocrinology

Volumn 155, Issue 1, 2014, Pages 47-55

  Gomez Sanchez, Celso E ^a   Oki, Kenji ^b  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE; ANGIOTENSIN II; CALCIMYCIN; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GUANINE NUCLEOTIDE BINDING PROTEIN; LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; MINERALOCORTICOID ANTAGONIST; POTASSIUM CHANNEL; TWIK RELATED ACIDSENSITIVE POTASSIUM CHANNEL 1; TWIK RELATED ACIDSENSITIVE POTASSIUM CHANNEL 3; TWIK RELATED ACIDSENSITIVE POTASSIUM CHANNEL 4; TWIK RELATED ACIDSENSITIVE POTASSIUM CHANNEL 5; UNCLASSIFIED DRUG;

ADRENAL CORTEX CELL; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CELL FUNCTION; CELL STRAIN HEK293; DEPOLARIZATION; ENZYME ACTIVITY; HORMONAL REGULATION; HORMONE RELEASE; HYPERALDOSTERONISM; MEMBRANE DEPOLARIZATION; MEMBRANE STEADY POTENTIAL; NONHUMAN; POTASSIUM CHANNELOPATHY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION; STEROIDOGENESIS;

EID: 84891410250     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1733     Document Type: Review

References (78)

1. Spät A, Hunyady L. Control of aldosterone secretion: A model for convergence in cellular signaling pathways. Physiol Rev. 2004; 84(2):489-539.
2. Rebuffat P, Mazzocchi G, Gottardo G, Nussdorfer GG. Further studies on the involvement of dopamine and somatostatin in the inhibitory control of the growth and steroidogenic capacity of rat adrenal zona glomerulosa. Exp Clin Endocrinol. 1989;93(1):73-81.
3. Veglio F, Pinna G, Rabbia F, Panarelli M, Bisbocci D, Melchio RC. Dopaminergic regulation of aldosterone secretion: Assessment in different subtypes of primary aldosteronism and in essential hypertension. J Internat Med Res. 1991;19:44-49.
4. Mazzocchi G, Malendowicz LK, Meneghelli V, Nussdorfer GG. Evidence that endogenous somatostatin (SRIF) exerts a tonic inhibitory effect on the rat renin-Angiotensin-Aldosterone system. In Vivo. 1992;6(1):9 -12.
5. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93(9):3266-3281.
6. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45(8):1243-1248.
7. Reincke M, Fischer E, Gerum S, et al. Observational study mortality in treated primary aldosteronism: The German Conn's registry. Hypertension. 2012;60(3):618-624.
8. Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: A controlled crosssectional study. Hypertension. 2013;62(2):331-336.
9. Lifton RP, Dluhy RG, Powers M, et al. A chimaeric 11β-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
10. Sukor N, Mulatero P, Gordon RD, et al. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families. J Hypertens. 2008;26(8):1577-1582.
11. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP.Anovel form ofhumanmendelian hypertension featuring nonglucocorticoid- remediable aldosteronism. J Clin Endocrinol Metab. 2008;93(8):3117-3123.
12. Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331(6018):768-772.
13. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235-240.
14. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci USA. 2012; 109(7):2533-2538.
15. Mlinar B, Biagi BA, Enyeart JJ. Losartan-sensitive AII receptors linked to depolarization-dependent cortisol secretion through a novel signaling pathway. J Biol Chem. 1995;270(36):20942-20951.
16. Matthews EK, Saffran M. Effect of ACTH on the electrical properties of adrenocortical cells. Nature. 1968;219(5161):1369-1370.
17. Lymangrover JR, Matthews EK, Saffran M. Membrane potential changes of mouse adrenal zona fasciculata cells in response to adrenocorticotropin and adenosine 3',5'-monophosphate. Endocrinology. 1982;110(2):462-468.
18. Quinn SJ, Cornwall MC, Williams GH. Electrophysiological responses to angiotensin II of isolated rat adrenal glomerulosa cells. Endocrinology. 1987;120(4):1581-1589.
19. Quinn SJ, Cornwall MC, Williams GH. Electrical properties of isolated rat adrenal glomerulosa and fasciculata cells. Endocrinology. 1987;120(3):903-914.
20. Kanazirska MV, Vassilev PM, Quinn SJ, Tillotson DL, Williams GH. Single K+ channels in adrenal zona glomerulosa cells. II. Inhibition by angiotensin II. Am J Physiol. 1992;263(4 pt 1):E760-E765.
21. Vassilev PM, Kanazirska MV, Quinn SJ, Tillotson DL, Williams GH. K+ channels in adrenal zona glomerulosa cells. I. Characterization of distinct channel types. Am J Physiol. 1992;263(4 pt 1): E752-E759.
22. Guagliardo NA, Yao J, Hu C, Barrett PQ. Minireview: Aldosterone biosynthesis: Electrically gated for our protection. Endocrinology. 2012;153(8):3579-3586.
23. Scholl UI, Goh G, Stölting G, et al. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45:1050-1054.
24. Szanda G, Rajki A, Spat A. Control mechanisms of mitochondrial Ca(2+) uptake - feed-forward modulation of aldosterone secretion. Mol Cell Endocrinol. 2012;353(1-2):101-108.
25. Brauneis U, Vassilev PM, Quinn SJ, Williams GH, Tillotson DL. ANG II blocks potassium currents in zona glomerulosa cells from rat, bovine, and human adrenals. Am J Physiol. 1991;260(5 pt 1): E772-E779.
26. PayetMD,Durroux T, Bilodeau L, Guillon G, Gallo-Payet N. Characterization of K+ and Ca2+ ionic currents in glomerulosa cells from human adrenal glands. Endocrinology. 1994;134(6):2589-2598.
27. Arrighi I, Bloch-Faure M, Grahammer F, et al. Altered potassium balance and aldosterone secretion in a mouse model of human congenital long QT syndrome. Proc Natl Acad Sci USA. 2001;98(15): 8792-8797.
28. Lotshaw DP. Characterization of angiotensin II-regulated K+ conductance in rat adrenal glomerulosa cells. J Membr Biol. 1997; 156(3):261-277.
29. Lotshaw DP. Effects ofK+channel blockers onK+channels, membrane potential, and aldosterone secretion in rat adrenal zona glomerulosa cells. Endocrinology. 1997;138(10):4167-4175.
30. Lotshaw DP. Biophysical and pharmacological characteristics of native two-pore domain TASK channels in rat adrenal glomerulosa cells. J Membr Biol. 2006;210(1):51-70.
31. Czirják G, Enyedi P. TASK-3 dominates the background potassium conductance in rat adrenal glomerulosa cells. Mol Endocrinol. 2002;16(3):621-629.
32. Davies LA, Hu C, Guagliardo NA, et al. TASK channel deletion in mice causes primary hyperaldosteronism. Proc Natl Acad Sci USA. 2008;105(6):2203- 2208.
33. Guagliardo NA, Yao J,HuC, et al. TASK-3 channel deletion in mice recapitulates low-renin essential hypertension. Hypertension. 2012; 59(5):999-1005.
34. Heitzmann D, Derand R, Jungbauer S, et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. Embo J. 2008;27(1):179-187.
35. Penton D, Bandulik S, Schweda F, et al. Task3 potassium channel gene invalidation causes low renin and salt-sensitive arterial hypertension. Endocrinology. 2012;153(10):4740-4748.
36. Enyeart JA, Danthi SJ, Enyeart JJ. TREK-1 K+ channels couple angiotensin II receptors to membrane depolarization and aldosterone secretion in bovine adrenal glomerulosa cells. Am J Physiol Endocrinol Metab. 2004;287(6):E1154- E1165.
37. Enyeart JJ, Danthi SJ, Liu H, Enyeart JA. Angiotensin II inhibits bTREK-1 K+ channels in adrenocortical cells by separate Ca2+- and ATP hydrolysis-dependent mechanisms. J Biol Chem. 2005; 280(35):30814-30828.
38. Liu H, Enyeart JA, Enyeart JJ. Angiotensin II inhibits native bTREK-1 K+ channels through a PLC-, kinase C-, and PIP2-independent pathway requiring ATP hydrolysis. Am J Physiol Cell Physiol. 2007;293(2):C682-C695.
39. OkamotoM,Nonaka Y, Takemori H, Doi J. Molecular identity and gene expression of aldosterone synthase cytochrome P450. Biochem Biophys Res Commun. 2005;338(1):325-330.
40. Brenner T, O'Shaughnessy KM. Both TASK-3 and TREK-1 twopore loop K channels are expressed in H295R cells and modulate their membrane potential and aldosterone secretion. Am J Physiol Endocrinol Metab. 2008;295(6):E1480-E1486.
41. Czirják G, Enyedi P. Formation of functional heterodimers between the TASK-1 and TASK-3 two-pore domain potassium channel subunits. J Biol Chem. 2002;277(7):5426-5432.
42. Nogueira EF, Gerry D, Mantero F, Mariniello B, Rainey WE. The role of TASK1 in aldosterone production and its expression in normal adrenal and aldosterone-producing adenomas. Clin Endocrinol (Oxf). 2010;73(1):22-29.
43. Czirják G, Fischer T, Spät A, Lesage F, Enyedi P. TASK (TWIKrelated acid-sensitive K+ channel) is expressed in glomerulosa cells of rat adrenal cortex and inhibited by angiotensin II. Mol Endocrinol. 2000;14(6):863-874.
44. Bandulik S, Penton D, Barhanin J, Warth R. TASK1 and TASK3 potassium channels: Determinants of aldosterone secretion and adrenocortical zonation. Horm Metab Res. 2010;42(6):450-457.
45. Bandulik S, Tauber P, Penton D, et al. Severe hyperaldosteronism in neonatal task3 potassium channel knockout mice is associated with activation of the intraadrenal Renin-Angiotensin system. Endocrinology. 2013;154(8):2712-2722.
46. Carey RM. Role of K+ channels in the pathophysiology of primary aldosteronism. Hypertension. 2012;59(3):534-536.
47. Akerstrom T, Crona J, Delgado Verdugo A, et al. Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One. 2012;7(7):e41926.
48. Azizan EA, Murthy M, Stowasser M, et al. Somatic mutations affecting the selectivity filter of KCNJ5 are frequent in 2 large unselected collections of adrenal aldosteronomas. Hypertension. 2012; 59(3):587-591.
49. Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates ofKCNJ5mutations in primary aldosteronism. Hypertension. 2012;59(3):592-598.
50. Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab. 2012;97:E1567-E1572.
51. Taguchi R, Yamada M, Nakajima Y, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab. 2012;97(4):1311-1319.
52. Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: Their structure, function, and physiological roles. Physiol Rev. 2010;90(1):291-366.
53. Koyrakh L, Luján R, Colón J, et al. Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J Neurosci. 2005; 25(49):11468-11478.
54. Kurachi Y, Ishii M. Cell signal control of the G protein-gated potassium channel and its subcellular localization. J Physiol. 2004; 554(pt 2):285-294.
55. Morishige K, Inanobe A, Yoshimoto Y, et al. Secretagogue-induced exocytosis recruits G protein-gated K+ channels to plasma membrane in endocrine cells. J Biol Chem. 1999;274(12):7969-7974.
56. Lüscher C, Slesinger PA. Emerging roles for G protein-gated inwardly rectifying potassium (GIRK) channels in health and disease. Nat Rev Neurosci. 2010;11(5):301-315.
57. Gregerson KA, Flagg TP, O'Neill TJ, et al. Identification of G protein- coupled, inward rectifier potassium channel gene products from the rat anterior pituitary gland. Endocrinology. 2001;142(7): 2820-2832.
58. Dibb KM, Rose T, Makary SY, et al. Molecular basis of ion selectivity, block, and rectification of the inward rectifier Kir3.1/Kir3.4 K(+) channel. J Biol Chem. 2003;278(49):49537-49548.
59. Murthy M, Azizan EA, Brown MJ, O'Shaughnessy KM. Characterization of a novel somatic KCNJ5 mutation delI157 in an aldosterone- producing adenoma. J Hypertens. 2012;30(9):1827-1833.
60. Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and earlyonset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97(8):E1532-E1539.
61. Oki K, Plonczynski MW, Lam ML, Gomez-Sanchez EP, Gomez- Sanchez CE. The potassium channel, Kir3.4 participates in angiotensin II-stimulated aldosterone production by a human adrenocortical cell line. Endocrinology. 2012;153(9):4328-4335.
62. Yow TT, Pera E, Absalom N, et al. Naringin directly activates inwardly rectifying potassium channels at an overlapping binding site to tertiapin-Q. Br J Pharmacol. 2011;163(5):1017-1033.
63. Oki K, Plonczynski MW, Luis Lam M, Gomez-Sanchez EP, Gomez- Sanchez CE. Potassium channel mutant KCNJ5 T158A expression in HAC-15 cells increases aldosterone synthesis. Endocrinology. 2012;153(4):1774-1782.
64. Wang T, Rowland JG, Parmar J, Nesterova M, Seki T, Rainey WE. Comparison of aldosterone production among human adrenocortical cell lines. Horm Metab Res. 2012;44(3):245-250.
65. Mulatero P, di Cella SM, Monticone S, et al. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab. 2012;97(3):881-889.
66. Williams TA, Monticone S, Crudo V, Warth R, Veglio F, Mulatero P. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. Hypertension. 2012;59(4):833-839.
67. Boulkroun S, Samson-Couterie B, Golib-Dzib JF, et al. Aldosteroneproducing adenoma formation in the adrenal cortex involves expression of stem/progenitor cell markers. Endocrinology. 2011; 152(12):4753-4763.
68. Beuschlein F, Boulkroun S, Osswald A, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45(4):440 -444, 444e441-442.
69. Azizan EA, Poulsen H, Tuluc P, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet. 2013;45:1055-1060.
70. Yingst DR, Davis J, Krenz S, Schiebinger RJ. Insights into the mechanism by which inhibition of Na,K-ATPase stimulates aldosterone production. Metabolism. 1999;48(9):1167-1171.
71. Antonipillai I, Schick K, Horton R. Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. J Clin Endocrinol Metab. 1996;81(6):2335-2337.
72. Decher N, Maier M, Dittrich W, et al. Characterization of TASK-4, a novel member of the pH-sensitive, two-pore domain potassium channel family. FEBS Lett. 2001;492(1-2):84-89.
73. Kim D, Gnatenco C. TASK-5, a new member of the tandem-pore K(+) channel family. Biochem Biophys ResCommun. 2001;284(4): 923-930.
74. Enyeart JJ, Xu L, Danthi S, Enyeart JA. An ACTH- and ATP-regulated background K+ channel in adrenocortical cells is TREK-1. J Biol Chem. 2002;277(51):49186-49199.
75. Sarzani R, Pietrucci F, Francioni M, et al. Expression of potassium channel isoforms mRNA in normal human adrenals and aldosterone- secreting adenomas. J Endocrinol Invest. 2006;29(2):147-153.
76. Ganz MB, Nee JJ, Isales CM, Barrett PQ. Atrial natriuretic peptide enhances activity of potassium conductance in adrenal glomerulosa cells. Am J Physiol. 1994;266(5 pt 1):C1357-C1365.
77. Sausbier M, Arntz C, Bucurenciu I, et al. Elevated blood pressure linked to primary hyperaldosteronism and impaired vasodilation in BK channel-deficient mice. Circulation. 2005;112(1):60-68.
78. Azizan EA, Lam BY, Newhouse SJ, et al. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa- and zona fasciculata-like tumors. J Clin Endocrinol Metab. 2012;97(5): E819-E829.